Skin advanced glycation end products as biomarkers of photosensitivity in schizophrenia.
Adult
Antipsychotic Agents
/ adverse effects
Arginine
/ analogs & derivatives
Biomarkers
/ analysis
Case-Control Studies
Female
Fluorometry
/ methods
Glycation End Products, Advanced
/ analysis
Humans
Lysine
/ analogs & derivatives
Male
Photosensitivity Disorders
/ chemically induced
Pyridoxal
/ analysis
Schizophrenia
/ drug therapy
Skin
/ chemistry
Ultraviolet Rays
/ adverse effects
advanced glycation end products
carbonyl stress
photosensitivity
schizophrenia
Journal
International journal of methods in psychiatric research
ISSN: 1557-0657
Titre abrégé: Int J Methods Psychiatr Res
Pays: United States
ID NLM: 9111433
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
28
10
2018
revised:
01
01
2019
accepted:
04
01
2019
pubmed:
1
2
2019
medline:
16
1
2020
entrez:
1
2
2019
Statut:
ppublish
Résumé
Photosensitivity to ultraviolet A (UVA) radiation from sunlight is an important side effect of treatment with antipsychotic agents. However, the pathophysiology of drug-induced photosensitivity remains unclear. Recent studies demonstrated the accumulation of advanced glycation end products (AGEs), annotated as carbonyl stress, to be associated with the pathophysiology of schizophrenia. In this study, we investigated the relationship among skin AGE levels, minimal response dose (MRD) with UVA for photosensitivity, and the daily dose of antipsychotic agents in patients with schizophrenia and healthy controls. We enrolled 14 patients with schizophrenia and 14 healthy controls. Measurement of skin AGE levels was conducted with AGE scanner, a fluorometric method for assaying skin AGE levels. Measurement of MRD was conducted with UV irradiation device. Skin AGE levels and MRD at 24, 48, and 72 hr in patients with schizophrenia showed a higher tendency for photosensitivity than in the controls, but the difference was statistically insignificant. Multiple linear regression analysis using skin AGE levels failed to show any influence of independent variables. MRD did not affect skin AGE levels. Photosensitivity to UVA in patients with schizophrenia receiving treatment with antipsychotic agents might not be affected by skin AGE levels.
Identifiants
pubmed: 30701623
doi: 10.1002/mpr.1769
pmc: PMC6877242
doi:
Substances chimiques
Antipsychotic Agents
0
Biomarkers
0
Glycation End Products, Advanced
0
Pyridoxal
3THM379K8A
Arginine
94ZLA3W45F
pentosidine
BJ4I2X2CQJ
Lysine
K3Z4F929H6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1769Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
J Invest Dermatol. 2012 Feb;132(2):315-23
pubmed: 21956123
Ann N Y Acad Sci. 2005 Jun;1043:740-9
pubmed: 16037301
Br J Dermatol. 2004 Apr;150(4):757-60
pubmed: 15099375
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1905-12
pubmed: 18835577
Biochem Biophys Res Commun. 1996 Sep 4;226(1):37-41
pubmed: 8806589
J Dermatol Sci. 2000 Mar;23 Suppl 1:S6-9
pubmed: 10764983
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):29-39
pubmed: 20828596
Arch Gen Psychiatry. 2010 Jun;67(6):589-97
pubmed: 20530008
Ann N Y Acad Sci. 2005 Jun;1043:290-8
pubmed: 16037251
Front Psychiatry. 2018 Mar 13;9:82
pubmed: 29593588
J Clin Invest. 1993 Jun;91(6):2463-9
pubmed: 8514858
Contact Dermatitis. 2001 Jun;44(6):373
pubmed: 11417527
Psychiatry Clin Neurosci. 2015 Aug;69(8):440-7
pubmed: 25601291
Schizophr Bull. 2014 Sep;40(5):1040-6
pubmed: 24062594
Case Rep Dermatol Med. 2018 Jun 25;2018:9242515
pubmed: 30046495
J Psychiatr Res. 2013 Aug;47(8):1044-8
pubmed: 23615188
Nephrol Dial Transplant. 2005 Dec;20(12):2661-9
pubmed: 16188903
Schizophr Bull. 2014 Nov;40(6):1366-73
pubmed: 24448481
Ann Dermatol Venereol. 1982;109(3):225-8
pubmed: 7114735
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 2;76:42-48
pubmed: 28282638
J Psychiatr Res. 2015 Jul-Aug;66-67:112-7
pubmed: 26001588
Nephron. 2001 May;88(1):30-5
pubmed: 11340347
J Photochem Photobiol B. 2005 Feb 1;78(2):155-64
pubmed: 15664503
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 2;76:145-154
pubmed: 28341443
Int J Methods Psychiatr Res. 2019 Mar;28(1):e1769
pubmed: 30701623
J Vis Exp. 2013 May 28;(75):e50175
pubmed: 23748556
Diabetes Technol Ther. 2011 Jul;13(7):773-9
pubmed: 21510765
Transl Psychiatry. 2015 Jul 14;5:e601
pubmed: 26171982
Glycoconj J. 2018 Apr;35(2):177-190
pubmed: 29305779
J Clin Psychiatry. 2017 Nov/Dec;78(9):1395-1401
pubmed: 28445633
Diabetologia. 2009 May;52(5):789-97
pubmed: 19274450
World J Psychiatry. 2016 Mar 22;6(1):102-17
pubmed: 27014601
Diabetes Technol Ther. 2013 Mar;15(3):269-72
pubmed: 23343332
Schizophr Res. 2016 Sep;176(1):3-13
pubmed: 25124519
J Clin Psychopharmacol. 2008 Apr;28(2):219-20
pubmed: 18344734
Neurosci Lett. 2015 Apr 23;593:51-5
pubmed: 25766756
Ann N Y Acad Sci. 2008 Apr;1126:53-8
pubmed: 18079473
J Photochem Photobiol B. 1998 Jun 15;44(1):69-76
pubmed: 9745729